Overview

A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)

Status:
Recruiting
Trial end date:
2025-08-31
Target enrollment:
Participant gender:
Summary
This is an open-label Phase 2 study which will evaluate the efficacy and safety of belzutifan in combination with cabozantinib in participants with advanced ccRCC. Belzutifan and cabozantinib will be administered orally once daily.
Phase:
Phase 2
Details
Lead Sponsor:
Peloton Therapeutics, Inc.